Pharma: Other News To Note
Thursday, May 24, 2012
Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, said the European Medicines Agency accepted the submission of a marketing authorization application for alogliptin, a selective dipeptidyl peptidase IV inhibitor in Type II diabetes.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.